HeartSciences Inc.
HSCSW
NASDAQ Capital Market0.05
USD
+0.00
- -
CIK
0001468492
ISIN
US42254E1120
CUSIP
42254E112
Return %
Stock
S&P500
1Y
-19.03
26.53
3Y
-62.14
76.60
5Y
-85.69
80.11
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Andrew Simpson
- Full Time Employees
- 15
- Sector
- Healthcare
- Industry
- Medical - Devices
- Address
- 550 Reserve Street Southlake TX United States of America 76092-1552
- IPO Date
- Jun 15, 2022
- CIK
- 0001468492
- Website
- heartsciences.com
- Similar Companies
- Business
- HeartSciences Inc. (Nasdaq: HSCS; HSCSW) develops artificial intelligence-enhanced electrocardiography (AI-ECG) solutions to expand ECG clinical utility for earlier heart disease detection in frontline and point-of-care settings worldwide; core products include the MyoVista wavECG, a resting 12-lead ECG device providing diagnostic insights on cardiac dysfunction such as impaired relaxation and ejection fraction alongside conventional ECG data, MyoVista Insights, a cloud-native software platform that modernizes legacy ECG systems, integrates with existing devices and hospital EHRs, and serves as a marketplace for proprietary and third-party AI-ECG algorithms, and a broad library of AI-ECG algorithms addressing conditions like aortic stenosis and left ventricular diastolic dysfunction. Founded in 2007 and headquartered in Southlake, Texas, the company operates in the medical devices sector, targeting hospitals, clinics, and mobile testing services with device-agnostic, low-cost hardware and cloud-based offerings designed for seamless clinical workflow integration. Recent developments encompass the May 2025 launch of MyoVista Insights with phased rollout to early adopters, impending FDA 510(k) submission for MyoVista wavECG incorporating age-adjusted diagnostics aligned with updated American Society of Echocardiography guidelines, FDA Breakthrough Device designation for its aortic stenosis algorithm, Centers for Medicare & Medicaid Services reimbursement approval at $128 per AI-ECG test, patent portfolio expansion to 44 granted worldwide including U.S. coverage for ECG-based echocardiographic parameter estimation, a name change from Heart Test Laboratories Inc. in October 2024, and $3.1 million raised via Reg A+ offering plus $0.9 million debt-to-equity conversion post-fiscal 2025 year-end to extend cash runway ahead of 2026 commercialization.